Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* in good health~* body mass index of 20 to 29.9 kg/m2~* female subjects must be either postmenopausal for at least 1 year, surgically sterile, abstinent, or agree to use an effective method of birth control~Exclusion Criteria:~* history or clinical manifestations of any clinically significant disorder~* history of hypersensitivity or allergies to any drug compound~* history of stomach or intestinal surgery or resection~* history of alcoholism or drug addiction within 1 year~* use of any tobacco-containing or nicotine-containing products within 6 months~* use of any other medications~* use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages; or foods or beverages with high levels of tyramine~* pregnancy, lactation, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
- 2 (Type: PLACEBO_COMPARATOR): Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
- 3 (Type: ACTIVE_COMPARATOR): Oral doses of 600mg linezolid given twice daily for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).